Here are 1-2 brief analogies for Jupiter Neurosciences (JUNS):

• Moderna for Resveratrol's Brain Delivery: Jupiter Neurosciences is like a specialized biotech company, similar to how Moderna developed a platform for mRNA delivery, but focused on engineering a superior delivery system for resveratrol to make it an effective treatment for neurological and neuro-inflammatory diseases.
• An Early Biogen for Resveratrol: Think of them as an early-stage biotech company (like a nascent Biogen, known for neurological disorders) but uniquely focused on unlocking the full therapeutic potential of resveratrol for conditions like Alzheimer's and rare neuro diseases by solving its critical bioavailability and delivery challenges.

• JOTROL™: A unique resveratrol platform product designed to deliver therapeutically effective doses of resveratrol for the treatment of neuro-inflammation, rare diseases (such as Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, MELAS, ALS), and larger disease areas like Mild Cognitive Impairment/early Alzheimer’s disease, without causing gastrointestinal side effects.

Jupiter Neurosciences (JUNS) is a clinical-stage research and development pharmaceutical company. According to the provided background information, the company has generated no revenues from product sales for the fiscal years ended December 31, 2020 and 2019, nor for the nine months ended September 30, 2021 and 2020.

Therefore, Jupiter Neurosciences currently does not have any major customers, as it is still in the development phase and has not yet brought a product to market.

Christer Rosén, Founder, Chairman & CEO

Christer Rosén is the primary founder and Chairman & CEO of Jupiter Neurosciences, Inc. Originally from Halmstad, Sweden, he started his first company, a discotheque, at age 17. After college, he founded a software consulting company and was involved in the entertainment business, including restaurants and a hotel. From 1997 through May 2015, he founded and served as the Chief Executive Officer and Chairman of EffRx Pharmaceuticals. At EffRx, he co-invented and developed Binosto®, an osteoporosis drug that received FDA and EU approvals and is now distributed in several countries worldwide.

Saleem Elmasri, CPA, CFO

Saleem Elmasri has served as Chief Financial Officer since January 2023. Since September 2020, he has been a Principal at Titan Advisory Services LLC, a boutique advisory firm providing financial operations and CFO services to early-stage companies. Mr. Elmasri was a Managing Director at DLA LLC, a professional services firm, from June 2019 to April 2021. He began his career at PricewaterhouseCoopers, where he worked on Fortune 500 clients, primarily in the Life Sciences and Pharmaceutical industry. He has over 15 years of experience in financial and management consulting.

Marshall Hayward, Ph.D., Co-Founder, CSO

Marshall Hayward is the Chief Scientific Officer at Jupiter Neurosciences, Inc. Between 2002 and 2013, Dr. Hayward served as Chief Scientific Officer at Effrx Pharmaceuticals, where he played a key role in the development and approval of the Binosto® product. He also held positions as Vice President of Business Development for Hurley Consulting Associates, LTD., Director of New Business Development at Rhoda Pharmaceutical Ingredients, and Director and Vice President of Analgesics Research and Development at SmithKline Beecham (UK). He is a co-inventor of Jupiter Neurosciences' proprietary technology.

Alexander Rosén, Co-Founder, CAO

Alexander Rosén is a Co-Founder and Chief Administrative Officer at Jupiter Neurosciences, Inc. (formerly Jupiter Orphan Therapeutics, Inc.), having been with the company since its inception. From February 2019 to July 2021, Mr. Rosén worked part-time as Controller and Head of Administration & Office Management at X-VAX Technology, Inc. Before his corporate career, he was a professional golfer, playing on various tours across North America and Europe.

Alison D. Silva, President & CBO

Alison D. Silva serves as President & Chief Business Officer. Previously, she was the Chief Executive Officer of Cotinga Pharmaceuticals (formerly Critical Outcome Technologies) from July 2016 through August 2021. In 2013, she co-founded The Microbiome Company, later rebranded to Synlogic Therapeutics, where she served as Executive Vice President and Chief Operating Officer until June 2016. Her other relevant experience in biotech and pharma includes co-founder and Vice President of Development at Marina Biotech, and co-founder and Director at The Orphan Group.

• Significant Dependence on Grant Funding for Operations and Development: Jupiter Neurosciences explicitly relies on grant funding, particularly from the National Institute on Aging (NIA), to finance its crucial clinical trials, including a recently submitted application for an $18.3 million Phase II trial in Mild Cognitive Impairment and early Alzheimer’s disease. The company states that "rejection of our future grant application may significantly delay the Company’s plans in connection with MCI and Alzheimer’s and may have a significant impact on the Company’s financial performance" and that "the Company may never receive any future grants or costs savings." This reliance on external, non-guaranteed funding poses a substantial risk to its ability to advance its product pipeline and sustain operations.
• High Risk of Clinical Trial Failure for its Sole Product Candidate, JOTROL™: As a clinical-stage pharmaceutical company, Jupiter Neurosciences' future is entirely dependent on the successful, costly, and lengthy progression of its lead product candidate, JOTROL™, through Phase II, Phase III, and subsequent regulatory approval. While Phase I results are reported as positive, a significant majority of drug candidates fail in later-stage trials due to lack of efficacy, safety concerns, or other unforeseen issues. Failure at any of these advanced stages would lead to a complete loss of investment in JOTROL™ and would severely impact the company's viability, given its focus on a single platform.

Jupiter Neurosciences (JUNS) is developing JOTROL™ to target several neurological conditions. The estimated addressable markets for these conditions are as follows:

• Mucopolysaccharidoses Type 1 (MPS I): The global mucopolysaccharidosis treatment market, which includes MPS I, was valued at USD 4.19 billion in 2025 and is predicted to reach approximately USD 11.49 billion by 2035. The MPS I segment held the largest share of the global market in 2025. Specifically for MPS I, the market size in the 7MM (United States, Germany, France, Italy, Spain, United Kingdom, and Japan) was approximately USD 145 million in 2024 and is projected to grow to USD 297 million in 2034. The U.S. market for MPS I was around USD 70 million in 2024.
• Friedreich's Ataxia (FA): The global Friedreich's Ataxia market size was estimated at USD 2.63 billion in 2024 and is expected to reach USD 3.59 billion by 2032. Another estimate places the global market at USD 1.12 billion in 2025, expected to reach USD 2.07 billion by 2030. North America held the largest revenue share, accounting for 41.5% in 2024.
• MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes): The market for MELAS syndrome across the top 7 major markets (US, EU4, UK, and Japan) reached a value of USD 170.5 million in 2024 and is expected to reach USD 512.2 million by 2035. The United States is noted as having the largest patient pool and representing the largest market for MELAS treatment.
• ALS (Amyotrophic Lateral Sclerosis): The global market for amyotrophic lateral sclerosis treatments was valued at USD 713.3 million in 2023 and is projected to grow to USD 1,271.6 million by 2033. Another report valued the global ALS treatment market at USD 752.0 million in 2024, poised to grow to USD 1,238.49 million by 2033. North America dominated the global market with a revenue share of 37.7% in 2023.
• Mild Cognitive Impairment (MCI) and early Alzheimer's disease (AD): The global Mild Cognitive Impairment market size was valued at USD 2.1 billion in 2022 and is expected to reach USD 3.5 billion by 2032. It was over USD 2.51 billion in 2025 and is anticipated to cross USD 4.29 billion by 2035. North America is the largest region in the MCI market, projected to hold a 45.4% share by 2035. For Alzheimer's disease, the global market was USD 5.10 billion in 2022 and is likely to reach USD 9.73 billion by 2030. The Alzheimer's disease diagnostics and treatment market is projected to rise from US$ 7.72 billion in 2025 to US$ 14.14 billion by 2032 globally. The Alzheimer's disease market in the 7MM (US, EU4, UK, Japan) is valued at approximately USD 5,048 million in 2025 and is projected to grow to USD 34,335 million by 2034. The U.S. accounted for approximately 54% of the total Alzheimer's disease market size in 7MM in 2023.
• TBI/Concussions: The global concussion market size was estimated at USD 6.58 billion in 2024 and is projected to reach USD 9.31 billion by 2030. Another source reported the global concussion market size at USD 8.2 billion in 2025, growing to USD 8.58 billion in 2026, and expected to reach USD 10.43 billion in 2030. The Traumatic Brain Injuries Assessment Market size was over USD 11.66 billion in 2025 and is poised to exceed USD 24.03 billion by 2035 globally. North America was the largest region in the concussion market in 2024, holding a 60.9% revenue share, and holds a 47.5% share in the traumatic brain injuries assessment market.

Expected Drivers of Future Revenue Growth for Jupiter Neurosciences (JUNS)

• Strategic Partnerships and Licensing Agreements for JOTROL™: As a clinical-stage company with a novel resveratrol platform, Jupiter Neurosciences is well-positioned to attract strategic partnerships or licensing agreements for its lead product candidate, JOTROL™. These agreements, potentially covering co-development, commercialization rights, or regional licenses for indications such as Mild Cognitive Impairment/early Alzheimer's disease or various rare diseases, could generate significant upfront payments and development milestone payments, which would constitute revenue growth. The company's lean operating model and reliance on external resources suggest an openness to such collaborations as a path to market.
• Commercialization of JOTROL™ in Rare Disease Indications: Jupiter Neurosciences is targeting several rare diseases, including Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS. Due to the potential for expedited regulatory pathways and orphan drug designations often associated with rare diseases, successful and rapid clinical development could lead to accelerated approval and initial product sales for JOTROL™ within the next 2-3 years, contributing to revenue growth.
• Achievement of Key Clinical Development Milestones for JOTROL™ in Mild Cognitive Impairment (MCI) and early Alzheimer’s disease: The company has identified MCI and early Alzheimer’s disease as a primary target in larger disease areas and has applied for significant grant funding for a Phase II trial. Positive results from such pivotal trials would substantially de-risk JOTROL™. While direct product sales in this large market are unlikely within a 2-3 year timeframe, successful advancement through these clinical stages would likely trigger significant milestone payments from existing or future strategic partnerships, or could increase the company's attractiveness for acquisition, leading to revenue generation.

Share Issuance

• Management, Scientific Advisory Board members, and business advisors are primarily compensated with equity securities of the company.

Inbound Investments

• The company received $1.76 million in full funding from the National Institute on Aging (NIA) in 2020 for its Phase I study.
• A grant application for $18.3 million for full funding, including corporate overhead, was recently submitted to NIA for a Phase II trial in Mild Cognitive Impairment (MCI) and early Alzheimer’s disease.